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Background
Cinaciquat (CIN) is a guanylate cyclase (sGC) activator
that induces cyclic GMP generation and vasodilation
preferentially in diseased vessels [1]. CIN has the poten-
tial to increase cardiac output in patients with acute
decompensated heart failure [2]. CIN is predominantly
and rapidly cleared by the liver [3], and thus, it was not
expected that the kidney function would have an influ-
ence on CIN clearance. Nevertheless, we determined the
pharmacokinetics of CIN in individuals with renal
impairment and age- and gender-matched healthy
volunteers with normal renal function [4].
Material and methods
In this non-randomized, non-blinded study, individuals
were grouped on the basis of their creatinine clearance
(CLcr) obtained from a 24 hour urine collection:
￿ Group 1 (healthy control): CLcr > 80 mL/min
￿ Group 2 (mild renal impairment): CLcr 50 - 80 mL/
min
￿ Group 3 (moderate renal impairment): CLcr 30 < 50
mL/min
￿ Group 4 (severe renal impairment): CLcr <3 0m L /
min (not on dialysis).
34 individuals received a single 4 hour infusion of 400
µg CIN at a constant rate of 100 µg/h. Plasma concentra-
tions of CIN were determined by high performance liquid
chromatography with mass spectrometry. Pharmacoki-
netic parameters were calculated by noncompartmental
analysis in WinNonlin Professional (version 4.1.a).
Results
There was no evidence of increased drug exposure in
individuals with renal impairment. The apparent volume
of distribution at steady state (Vss) was slightly increased
in individuals with renal impairment (Table 1). More-
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Table 1 Pharmacokinetic parameters of CIN in healthy controls and individuals with mild, moderate and severe renal
impairment, showing values as geometric mean (coefficient of variation, %) except for fu which is expressed as
arithmetic mean (standard deviation).
Renal function group CL (L/h) Vss (L) t½ (h) fu %
Group 1: Healthy control (n=9) 36.12 (12.3) 18.70 (19.2) 1.56 (53.4%) 0.45 (0.12)
Group 2: Mild renal impairment (n=8) 41.43 (15.3) 26.56 (37.6) 1.72 (65.1%) 0.42 (0.07)
Group 3: Moderate renal impairment (n=9) 40.58 (18.9) 24.02 (27.1) 1.58 (49.6%) 0.53 (0.15)
Group 4: Severe renal impairment (n=8) 51.81 (26.2) 23.51 (18.7) 1.08 (64.0%) 0.66 (0.16)
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to increase with progression of renal impairment, which
can be explained by an increased hematocrit in indivi-
duals with renal impairment, considering the fact that
CIN does not distribute in blood cells. The resulting
terminal half-life (t1/2) in individuals with renal impair-
ment was comparable to the value found in healthy con-
trols. The fraction of CIN unbound (fu)i np l a s m aw a s
very low (< 1%) in all groups ,a n dt e n d e dt oi n c r e a s e
with progression of renal impairment, which might be
caused by a decrease of albumin concentration. The
incidence of adverse events (mostly mild) was similar in
all groups.
Conclusion
The pharmacokinetic results are similar to previous
results observed in healthy young men [3]. The CL of
CIN is dependent on hematocrit, which is reduced in
renal impairment. However, as hematocrit changes are
limited in magnitude (i.e. 0.3-0.5), the effect is on CL is
also clearly limited. Thus, no dose adjustment of CIN is
recommended for renal impairment.
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